Biocon's Breakthrough: Bosaya and Vevzuo Approved by Health Canada
Biocon Ltd has received approval from Health Canada for its biosimilars, Bosaya and Vevzuo, intended for treating osteoporosis and cancer-related bone complications. This approval underscores Biocon's commitment to accessible biologic therapies and enhances their global portfolio in immunology and oncology sectors.
- Country:
- India
Biocon Ltd announces a significant achievement as Health Canada grants approval for its biosimilars, Bosaya and Vevzuo. These treatments target osteoporosis and bone complications associated with cancer.
The approvals, effective April 3, 2026, mark a milestone for Biocon as it bolsters its presence in global markets.
CEO Shreehas Tambe emphasizes the company's dedication to delivering affordable biologic therapies, underscoring the role of denosumab products in enhancing bone health without compromising quality or efficacy.
(With inputs from agencies.)
Advertisement
ALSO READ
ADHD Drugs: A New Hope for Cancer-Related Fatigue
Strict action will be taken against anyone involved in malpractice or it'll become cancer-like social malaise: Pradhan on NEET irregularities.
Revolution Medicines' Promising Pancreatic Cancer Drug: A Race for Early Access
TDB-DST Advances Next-Generation Cancer Immunotherapy with Dual-Target CAR-T Project
Alembic Pharmaceuticals Secures USFDA Nod for Prostate Cancer Drug
Google News